AOA Dx Announces Initial Validation of Novel Tumor Gangliosides as Promising Diagnostic Markers for Early Detection of Ovarian Cancer

Boston, MA:  AOA Dx announces initial validation of GD2 and GD3 tumor marker gangliosides as novel diagnostic markers for early detection of ovarian cancer. AOA Dx results will be presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.

Ovarian cancer is the deadliest gynecological disease. Up to 95% of women with ovarian cancer have symptoms for many months and consult a doctor, but the average time to diagnosis is 9 months. An early stage diagnostic test may enable detection of malignancy helping to expedite workup and treatment plans. Detection of ovarian cancer at early-stages has a 5-year survival rate of greater than 90%, but when diagnosed at advanced stages, the 5-year survival rate is less than 30%.

AOA Dx incorporated a novel panel of tumor gangliosides with a proprietary algorithm in the AKRIVIS GD(™) Test. This combination achieved an AUC of 0.969 for detection of ovarian cancer in early stages. This is a significant improvement over the standard of care, the CA125 test, which lacks sensitivity in early stages of the disease.

“Today, ovarian cancer takes the lives of far too many women. The challenge of early diagnosis has been one that many have tried to tackle, but until today, we haven’t seen anything with the potential to catch the disease in early stages. Our initial validation of AKRIVIS GD shows promising results, and an exciting first step towards improving the early detection of ovarian cancer” said Oriana Papin-Zoghbi, CEO and Co-Founder of AOA Dx.

AOA Dx developed a novel approach to evaluate tumor marker gangliosides in liquid biopsies for early cancer detection. AKRIVIS GD detected ovarian cancer in all subtypes and stages, including stage I and II, the most challenging stages to diagnose.

“Our research on tumor marker gangliosides over the past years has shown their potential as top targets for early detection of cancer. In our latest research, we were able to correctly identify disease in over 90% of early stage subjects.” said Professor Uri Saragovi, Principal Investigator.

The AKRIVIS GD novel diagnostic panel may enable accurate detection of malignancy helping expedite workup and treatment plans. Validation of AKRIVIS GD may alleviate costs and increase survival rates.

AOA Dx will continue to focus on validating these and additional biomarkers in independent and prospective studies leading to opportunities to improve early cancer detection.

About AOA Dx Inc.
AOA Dx is pioneering the field of Glycolipids, a new frontier in diagnostics. The proprietary biomarker technology in glycolipids detects early-stage cancer in blood by quantifying circulating gangliosides across multiple cancers and utilizing data science and AI to develop highly accurate diagnostic tests. AOA Dx is focused on women’s health with our first platform product detecting early-stage ovarian cancer, the deadliest gynecological cancer.

Corporate Communications